Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study

Vijaya Raj Bhatt, Baojiang Chen, Stephanie J. Lee

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Younger patients with intermediate or high-risk acute myeloid leukemia (AML) obtain overall survival benefit from the upfront use of hematopoietic cell transplantation (HCT). We queried the National Cancer Database to study 19,897 younger patients (18-60 years) with intermediate or high-risk AML reported between 2003-2012. Multivariable logistic regression analysis was performed to identify variables associated with the utilization of HCT. Approximately 18.5% of younger patients received HCT as a part of initial therapy. A lower rate of utilization of HCT was associated with receipt of care in a non-academic hospital, African American race, male sex, age group 50-60 years, Charlson comorbidity score of ≥1, uninsured status, Medicaid or Medicare insurance, and lower educational or income status. The use of HCT in younger patients varies based on non-biologic factors such as race, hospital type, insurance, educational, and income status. Socioeconomic and health system factors contribute to disparity in the uptake of HCT in the US.

Original languageEnglish (US)
Pages (from-to)873-879
Number of pages7
JournalBone marrow transplantation
Volume53
Issue number7
DOIs
StatePublished - Jul 1 2018

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Use of hematopoietic cell transplantation in younger patients with acute myeloid leukemia: A National Cancer Database Study'. Together they form a unique fingerprint.

  • Cite this